Clinical Trials Browser

Phase 3 × Docetaxel × Genitourinary × Clear all

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06925737 2026-03-13

MK-2400-001

Phase 3 Recruiting

Prostatic Neoplasms

NCT07225946 2026-03-13

KLK2-PASenger

Phase 3 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

NCT06931340 2026-03-04

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT05538663 2026-03-02

BRIDGE

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT07419295 2026-02-19

TroFuse-031

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT06439225 2026-02-11

OPTION-DDR

Phase 3 Recruiting

Prostatic Neoplasms

NCT03390504 2026-02-02

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT06764485 2026-01-28

rechARge

Phase 3 Recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06592924 2026-01-14

TRIPLE-SWITCH

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 1 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT00309985 2025-12-11

CHAARTED

Phase 3 Completed

790 enrolled 11 charts

Metastatic Hormone-sensitive Prostate Cancer

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06320067 2025-09-26

STAMPEDE2

Phase 3 Recruiting

Prostate Cancer Metastatic

NCT06857175 2025-09-12

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT04527991 2025-08-03

TROPiCS-04

Phase 3 Completed

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT03834506 2025-07-18

KEYNOTE-921

Phase 3 Completed

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

Phase 3 Completed

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02288247 2025-04-08

PRESIDE

Phase 3 Completed

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Phase 3 Recruiting

Genital Diseases, Male, Prostatic Diseases

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03761225 2023-09-29

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Completed

Metastatic Castrate Resistant Prostate Cancer

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT05983783 2023-08-09

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Phase 3 Recruiting

Prostatic Neoplasms

NCT00651326 2023-08-04

DART

Phase 3 Terminated

Prostatic Neoplasms

NCT00027859 2023-06-15

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT04139772 2023-03-24

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Phase 3 Unknown

Metastatic Castration-resistent Prostate Cancer

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Phase 3 Active not recruiting

788 enrolled 10 charts

Prostatic Neoplasms

NCT00055731 2023-01-18

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase 3 Completed

Prostatic Neoplasms

NCT00288080 2022-06-21

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Phase 3 Completed

612 enrolled 11 charts

Prostatic Neoplasms

NCT00134056 2021-10-27

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Phase 3 Completed

1,038 enrolled 20 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02256436 2021-09-20

MK-3475-045

Phase 3 Completed

542 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03119857 2021-08-18

Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14

Phase 3 Unknown

Prostatic Neoplasms

NCT00104715 2021-02-21

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT00030654 2020-10-22

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT02302807 2019-08-01

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Phase 3 Completed

931 enrolled 21 charts

Urinary Bladder Neoplasms

NCT01308567 2019-06-05

FIRSTANA

Phase 3 Completed

1,168 enrolled 17 charts

Prostatic Neoplasms

NCT00988208 2018-04-04

Mainsail

Phase 3 Completed

1,059 enrolled 27 charts

Prostatic Neoplasms

NCT02044354 2017-08-08

CABA-DOC

Phase 3 Unknown

Metastatic Castration-resistant Prostate Cancer

NCT00744497 2016-10-17

READY

Phase 3 Completed

1,930 enrolled 23 charts

Prostatic Neoplasms

NCT01188187 2016-10-14

SYNERGY

Phase 3 Completed

Prostatic Neoplasms

NCT01083615 2016-10-12

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Phase 3 Terminated

Castrate-Resistant Prostate Cancer

NCT00519285 2016-07-22

VENICE

Phase 3 Completed

1,224 enrolled 21 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00041171 2016-07-12

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Phase 3 Withdrawn

BreastCNSGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma